Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has garnered significant attention thanks to the success of tirzepatide. This dual GIP/GLP-1 receptor agonist has redefined the treatment of type 2 diabetes and obesity, showing exceptional results in glycemic control and weight loss. In addition to these established indications, tirzepatide is being explored for a range of other conditions, including cardiovascular health, non-alcoholic steatohepatitis (NASH), sleep apnea, and more, underscoring the expansive potential of GIPR-targeting therapies.
The increasing interest in GIPR is reflected in the growing number of clinical trials, with companies like Amgen also advancing GIPR-targeting therapies for a range of conditions. GIPR’s ability to regulate insulin secretion, fat metabolism, and appetite positions it as a versatile target in treating metabolic diseases and beyond. The continued success of GIPR-targeting therapies in 2024 marks just the beginning of its potential, offering exciting possibilities for millions of patients with a wide array of conditions that extend well beyond diabetes and obesity.
The Protein Imager rendering displays the cryo-EM structure of the tirzepatide-bound human GIPR-Gs complex (PDB entry 7FIY).
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
1. Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
2. Clovertex website